Galapagos Biotech

We are a fully integrated biotechnology company focused on discovering, developing and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in the European Union, Norway, Great Britain, and Japan. Our mission is to develop transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve quality of life of patients across the globe. Through the combined acquisition of CellPoint and AboundBio, we are adding a new therapy and disease area to its current small molecules portfolio: cell therapy, a potential transformative treatment of different types of cancer. It propels us into next-generation cell therapies, while significantly broadening our portfolio and capabilities. We employ more than 1,300 employees worldwide, with sites in Belgium (international headquarters), the Netherlands, France, Germany, Austria, Italy, Spain, the Nordics, Switzerland, the UK and the US.